NCT07241182Recruiting
Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy
The Effects of Antrodia Cinnamomea Fruiting Body Extract on Quality of Life and Chemotherapy Side Effects in Patients With Lung Cancer Undergoing Platinum-Based Chemotherapy
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy. Participants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea/vomiting scores, sleep quality, quality of life, and cancer symptoms.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 4 Sept 2025
- Start date
- 24 Nov 2025
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Tri-Service General Hospital (TSGH)
- Diseases
- Lung cancer
- NCT number
- NCT07241182
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 24 Nov 2025 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Within 30 days prior to trial entry, unexplained fever ≥38.5°C for 7 consecutive days or chronic diarrhea for 15 consecutive days.
- Currently receiving hormone therapy.
- Patients with known allergies/allergic reactions to the investigational product or any components in their formulations.
- Patients currently taking supplements containing Antrodia camphorata extract.
Other illness
- Major cardiac disease or arrhythmia severe enough that the attending physician considers the patient unsuitable for trial participation.
- Patients with currently active acute infections.
Lab values
- Within 14 days prior to trial entry, laboratory data showing abnormal liver function, abnormal kidney function
Other
- Inability to comply with timely supplementation administration.
- Major neuropathy.
Who the study is looking for
- Pathologically and radio-graphically diagnosed lung cancer
- Age greater than 18 years
- Received platinum-based chemotherapy
- Life expectancy of six months or longer
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tri-Service General Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.